Management of Enoxaparin in Patients with Brain Bleed

Immediate Management of Active Intracranial Hemorrhage

The Neurocritical Care Society recommends discontinuing Lovenox immediately when brain bleeding is confirmed or suspected 1, 2, 3
For patients on therapeutic-dose enoxaparin with intracranial hemorrhage, protamine reversal is strongly recommended (strong recommendation, moderate evidence) 1, 2, 3
The American College of Critical Care Medicine suggests that if enoxaparin was given within 8 hours, administer protamine 1 mg per 1 mg of enoxaparin (maximum 50 mg single dose) 1, 3
If life-threatening bleeding persists or the patient has renal insufficiency, consider redosing protamine at 0.5 mg per 100 anti-Xa units or per 1 mg of enoxaparin 1, 3

The Neurocritical Care Society states that for prophylactic subcutaneous enoxaparin, routine reversal is NOT recommended unless the aPTT is significantly prolonged 1, 2, 3, 5

The American College of Critical Care Medicine advises never giving therapeutic anticoagulation during active intracranial bleeding 1, 4
Do not delay reversal while waiting for anti-Xa levels—reversal decisions should be based primarily on bleeding severity and dosing history, not laboratory testing 1, 2
Do not restart enoxaparin before repeat imaging confirms hemorrhage stability—premature resumption increases rebleeding risk 4, 6
The American College of Critical Care Medicine recommends not using protamine for pentasaccharides (fondaparinux)—it is ineffective for these agents; use aPCC or rFVIIa instead 1, 2

The American Society of Hematology suggests that anticoagulation can be used in patients with intracranial malignancies, with symptomatic intracranial hemorrhage rates of 0-7% when using LMWH 7
The decision to resume anticoagulation after intracranial hemorrhage typically occurs around 1 week, balancing the risk of rebleeding against thrombotic complications, though this must be individualized based on imaging stability and indication strength 4